UY26693A1 - Una composición farmacéutica y procedimiento de tratamiento de enfermedades de disfunción cognitiva en un mamífero - Google Patents

Una composición farmacéutica y procedimiento de tratamiento de enfermedades de disfunción cognitiva en un mamífero

Info

Publication number
UY26693A1
UY26693A1 UY26693A UY26693A UY26693A1 UY 26693 A1 UY26693 A1 UY 26693A1 UY 26693 A UY26693 A UY 26693A UY 26693 A UY26693 A UY 26693A UY 26693 A1 UY26693 A1 UY 26693A1
Authority
UY
Uruguay
Prior art keywords
mammal
pharmaceutical composition
cognitive dysfunction
diseases
procedure
Prior art date
Application number
UY26693A
Other languages
English (en)
Inventor
Edmund Patrick Harrigan
Steven Bradley Sands
Jotham Wadsworth Coe
Brian Thomas O Neill
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY26693A1 publication Critical patent/UY26693A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición farmacéutica y un procedimiento de tratamiento de enfermedades de disfunción cognitiva en un mamífero, que comprende la administración de un agonista parcial del receptor de nicotina o una sal farmacéuticamente aceptable del mismo; y un inhibidor de acetilcolinesterasa, un inhibidor de butilcolinesterasa, un agente estrogénico, un modulador selectivo del receptor de estrógenos o un agonista muscarínico, o una sal farmacéuticamente aceptable de los mismos; y un vehículo farmacéuticamente aceptable.
UY26693A 2000-05-09 2001-05-07 Una composición farmacéutica y procedimiento de tratamiento de enfermedades de disfunción cognitiva en un mamífero UY26693A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20279900P 2000-05-09 2000-05-09

Publications (1)

Publication Number Publication Date
UY26693A1 true UY26693A1 (es) 2001-12-28

Family

ID=22751325

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26693A UY26693A1 (es) 2000-05-09 2001-05-07 Una composición farmacéutica y procedimiento de tratamiento de enfermedades de disfunción cognitiva en un mamífero

Country Status (16)

Country Link
US (2) US20010036949A1 (es)
EP (1) EP1280554A2 (es)
JP (1) JP2003532670A (es)
AR (1) AR028426A1 (es)
AU (1) AU2001248699A1 (es)
BR (1) BR0110487A (es)
CA (1) CA2409720A1 (es)
EC (1) ECSP014065A (es)
GT (1) GT200100075A (es)
MX (1) MXPA02011051A (es)
PA (1) PA8516701A1 (es)
PE (1) PE20011256A1 (es)
SV (1) SV2002000440A (es)
TN (1) TNSN01068A1 (es)
UY (1) UY26693A1 (es)
WO (1) WO2001085145A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050063998A1 (en) * 1999-10-26 2005-03-24 Francois Marc Karel Jozef Oral solution containing galantamine and a sweetening agent
EP2140868A1 (en) * 2000-03-03 2010-01-06 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments associated with or caused by chemotherapy
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
IL157881A0 (en) * 2001-04-20 2004-03-28 Pfizer Prod Inc Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
EP1420773A1 (en) * 2001-08-31 2004-05-26 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
AU2003270446A1 (en) * 2002-09-25 2004-04-19 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
WO2005000806A2 (en) * 2003-06-10 2005-01-06 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
US8299062B2 (en) * 2003-09-17 2012-10-30 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
KR101255074B1 (ko) 2003-10-01 2013-04-16 아돌로 코포레이션 스피로시클릭 헤테로시클릭 유도체 및 이의 사용 방법
US20060019938A1 (en) * 2003-12-31 2006-01-26 Beer Tomasz M Estrogen administration for treating male cognitive dysfunction or improving male cognitive function
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
US20050182044A1 (en) * 2004-02-17 2005-08-18 Bruinsma Gosse B. Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
JP2007537294A (ja) * 2004-05-14 2007-12-20 ザ・ジョンズ・ホプキンス・ユニバーシティー Ｇａｂａｂレセプターアンタゴニストとアセチルコリンエステラーゼインヒビターとの同時投与により認識機能を改善するための方法
EP1749017A2 (en) * 2004-05-27 2007-02-07 MIGENIX Corp. Compounds and methods for cytoprotection
EP2258359A3 (en) * 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) * 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
US7576207B2 (en) 2006-04-06 2009-08-18 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
GB0607952D0 (en) * 2006-04-21 2006-05-31 Minster Res Ltd Novel treatment
GB0607946D0 (en) * 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
JP2010503669A (ja) 2006-09-12 2010-02-04 アドラー コーポレーション 認知機能の強化のためのｎ含有スピロ化合物の使用
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
EP2117540A1 (en) 2007-03-01 2009-11-18 Probiodrug AG New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
SG178953A1 (en) 2009-09-11 2012-04-27 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP2533645B1 (en) 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
US8846061B1 (en) 2011-03-08 2014-09-30 Mark S. Bezzek Multivitamin-mineral regimens for longevity and wellness
US8349376B1 (en) 2011-03-08 2013-01-08 Bezzek Mark S Anti-dementia regimen
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
WO2012142039A1 (en) * 2011-04-15 2012-10-18 University Of North Dakota Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
BR112017025031B1 (pt) 2015-05-22 2023-03-21 Agenebio, Inc Composições farmacêuticas de liberação prolongada de levetiracetam
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218383B1 (en) * 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders

Also Published As

Publication number Publication date
US20030130303A1 (en) 2003-07-10
ECSP014065A (es) 2003-01-13
GT200100075A (es) 2001-12-31
CA2409720A1 (en) 2001-11-15
PE20011256A1 (es) 2001-12-29
TNSN01068A1 (fr) 2005-11-10
JP2003532670A (ja) 2003-11-05
PA8516701A1 (es) 2002-09-17
AU2001248699A1 (en) 2001-11-20
AR028426A1 (es) 2003-05-07
SV2002000440A (es) 2002-10-24
WO2001085145A8 (en) 2001-12-13
US20010036949A1 (en) 2001-11-01
WO2001085145A3 (en) 2002-06-13
WO2001085145A2 (en) 2001-11-15
EP1280554A2 (en) 2003-02-05
MXPA02011051A (es) 2003-03-10
BR0110487A (pt) 2003-04-01

Similar Documents

Publication Publication Date Title
UY26693A1 (es) Una composición farmacéutica y procedimiento de tratamiento de enfermedades de disfunción cognitiva en un mamífero
AR026165A1 (es) Dispositivo para la administracion de drogas.
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
NO993520D0 (no) Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon
AR016217A1 (es) Composicion farmaceutica que comprende un modulador dispositivo de un agonista receptor nicotinico, metodo para el tratamiento de un trastorno asociado conuna transmision reducida de nicotina, metodo para identificar un agonista repector nicotinico, uso de un modulador positivo de un agonista recept
WO2001054679A3 (en) Transdermal composition containing an anesthetic and a vasodilator agent
AR002355A1 (es) Composiciones y metodos para administracion local de agentes farmaceuticamente activos.
GT200100055A (es) Una composicion farmaceutica para el tratamiento del dolor agudo, cronico y/o el dolor neuropatico y las migrañas.
CO5670327A2 (es) Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion
ES2190075T3 (es) Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.
CO5170495A1 (es) Composiciones farmaceuticas para prevencion y tratamiento de enfermedades amiloidogenicas
DK1289517T3 (da) Farmaceutiske sammensætninger indeholdende cannabidiolderivater
BG105534A (en) 5ht1 means and method for the treatment of migraine
HUP0103078A2 (hu) Készítmények és eljárások szürkehályog kezelésére
ES2195638T3 (es) Preparaciones de combinaciones farmaceuticas en forma solida de dosificacion que contienen cardevilol e hidroclorotiazida.
AR019699A1 (es) Composicion farmaceutica para el tratamiento de disfuncion de la evacuacion y uso de la misma para la preparacion de un agente terapeutico
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
EP1254668A3 (en) Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression
EP1213031A3 (en) Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist
CO5261595A1 (es) Composiciones farmaceuticas que contienen una combinacion de salmeterol e ipratropium
NO20042758L (no) Fremgangsmate for behandling av en pasient som krever analgesi.
EP1192952A3 (en) Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
MXPA05010871A (es) Metodos para administrar estrogenos y progestinas.
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
TR200200683T2 (tr) Oral kontrollü salıverme formülasyonları.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20131104